Hepatocellular Carcinoma : Fenitab is indicated for the treatment of patients with unresectable hepatocellular carcinoma (HCC). Renal Cell Carcinoma : Fenitab is indicated for the treatment of patients with advanced renal cell carcinoma (RCC).
Sorafenib is a kinase inhibitor that decreases tumor cell proliferation. Sorafenib was shown to inhibit multiple intracellular (CRAF, BRAF and mutant BRAF) and cell surface kinases (KIT, FLT-3, RET, VEGFR-1, VEGFR-2, VEGFR-3, and PDGFR-β). Several of these kinases are thought to be involved in tumor cell signaling, angiogenesis, and apoptosis. Sorafenib inhibited tumor growth and angiogenesis of human hepatocellular carcinoma and renal cell carcinoma, and several other human tumor xenografts in immunocompromised mice.
The recommended daily dose of Sorafenib is 400 mg tablets taken twice daily without food (at least 1 hour before or 2 hours after a meal). Treatment should continue until the patient is no longer clinically benefiting from therapy or until unacceptable toxicity occurs. Management of suspected adverse drug reactions may require temporary interruption and/or dose reduction of Sorafenib therapy. When dose reduction is necessary, the Sorafenib dose may be reduced to 400 mg once daily. If additional dose reduction is required, Sorafenib may be reduced to a single 400 mg dose every other day. Recommended regimens and treatment duration for Sorafenib therapy. Grade 1: Numbness, dysesthesia, paresthesia, tingling, painless swelling, erythema or discomfort of the hands or feet which does not disrupt the patient's: Any occurrence : Continue treatment with Sorafenib and consider topical therapy for symptomatic relief. Grade 2: Painful erythema and swelling of the hands or feet and/ or discomfort affecting the patient’s normal activities 1st occurrence : Continue treatment with Sorafenib and consider topical therapy for symptomatic relief. If no improvement within 7 days, see below. No improvement within 7 days or 2nd or 3rd occurrence : Interrupt Sorafenib treatment until toxicity resolves to Grade 0-1 When resuming treatment, decrease Sorafenib dose by one dose level (400 mg daily or 400 mg every other day). 4th occurrence : Discontinue Sorafenib treatment. Grade 3: Moist desquamation, ulceration, blistering or severe pain of the hands or feet, or severe discomfort that causes the patient to be unable to work or perform activities of daily living: 1st or 2nd occurrence : Interrupt Sorafenib treatment until toxicity resolves to Grade 0-1 When resuming treatment, decrease Sorafenib dose by one dose level (400 mg daily or 400 mg every other day). 3rd occurrence : Discontinue Sorafenib treatment. No dose adjustment is required on the basis of patient age, gender, or body weight. Missed doses: If a dose of Sorafenib is missed, skip the missed dose, and take next dose at regular time. Do not double your dose of Sorafenib.
Always consult a registered doctor before taking any medicine. This information is for general knowledge only.
Serious adverse reactions are cardiac ischemia, infarction, hemorrhage, hypertension, hand-foot skin reaction and rash, gastrointestinal perforation, wound healing complications.
Sorafenib is contraindicated in patients with known severe hypersensitivity to Sorafenib or any other component of Sorafenib. Sorafenib in combination with carboplatin and paclitaxel is contraindicated in patients with squamous cell lung cancer.
Carboplatin and Paclitaxel : Fenitab in combination with carboplatin and paclitaxel is contraindicated in patients with squamous cell lung cancer, due to increased mortality observed with the addition of Fenitab compared to those treated with carboplatin and paclitaxel alone. No definitive cause was identified for this finding. UGT1A1 and UGT1A9 Substrates : Systemic exposure to substrates of UGT1A1 and UGT1A9 may increase when co-administered with Fenitab Docetaxel : Concomitant use of Docetaxel (75 or 100 mg/m2 administered every 21 days) with Fenitab (200 or 400 mg twice daily), administered with a 3-day break in dosing around administration of Docetaxel, resulted in a 36-80% increase in Docetaxel AUC and a 16-32% increase in Docetaxel Cmax. Caution is recommended when Fenitab is co-administered with Docetaxel Doxorubicin: Concomitant treatment with Fenitab resulted in a 21% increase in the AUC of Doxorubicin. Caution is recommended when administering Doxorubicin with Fenitab. Fluorouracil : Both increases (21%-47%) and decreases (10%) in the AUC of Fluorouracil were observed with concomitant treatment with Fenitab. Caution is recommended when Fenitab is co-administered with Fluorouracil/Leucovorin. CYP2B6 and CYP2C8 Substrates : Systemic exposure to substrates of CYP2B6 and CYP2C8 is expected to increase when co-administered with Fenitab. CYP3A4 Inducers : Continuous concomitant administration of Fenitab and Rifampicin resulted in an average 37% reduction of Fenitab AUC. Other inducers of CYP3A4 activity (for example, Hypericum perforatum also known as St. John’s wort, Phenytoin, Carbamazepine, Phenobarbital, and Dexamethasone) may also increase metabolism of Fenitab and thus decrease Fenitab concentrations. CYP3A4 Inhibitors and CYP Isoform Substrates : Fenitab metabolism is unlikely to be altered by CYP3A4 inhibitors and is unlikely to alter the metabolism of substrates of these enzymes. P-glycoprotein Substrates : Fenitab is an inhibitor of P-glycoprotein in vitro, therefore may increase the concentrations of concomitant drugs that are P-glycoprotein substrates. CYP Enzyme Induction : CYP1A2 and CYP3A4 activities were not altered after treatment of cultured human hepatocytes with Fenitab, indicating that Fenitab is unlikely to be an inducer of CYP1A2 or CYP3A4. Combination with other Antineoplastic Agents : Fenitab had no effect on the pharmacokinetics of gemcitabine or oxaliplatin. Neomycin : Coadministration of Fenitab with oral Neomycin should be carefully considered because average plasma exposure (AUC) of Fenitab was decreased by 54%.
Cardiac ischemia, infarction : Temporary or permanent discontinuation of Fenitab should be considered in patients who develop cardiac ischemia and/or infarction. Risk of Hemorrhage : An increased risk of bleeding may occur following Fenitab administration. There was one fatal hemorrhage in each treatment group in RCC Study. If any bleeding necessitates medical intervention, permanent discontinuation of Fenitab should be considered. Risk of Hypertension : In the HCC study, hypertension was reported in approximately 9.4% and In RCC Study, hypertension was reported in approximately 16.9% of Fenitab -treated patients. In cases of severe or persistent hypertension, despite institution of antihypertensive therapy, temporary or permanent discontinuation of Fenitab should be considered. Risk of Dermatologic Toxicities : Hand-foot skin reaction and rash represent the most common adverse reactions attributed to Fenitab. Risk of Gastrointestinal Perforation : In the event of a gastrointestinal perforation, Fenitab therapy should be discontinued. Warfarin Co-Administration : Patients taking concomitant warfarin should be monitored regularly for changes in prothrombin time, INR or clinical bleeding episodes. Wound Healing Complications : Resume Fenitab therapy following a major surgical intervention should be based on clinical judgment of adequate wound healing. Use of Fenitab in combination with Carboplatin and Paclitaxel in Non-small Cell Lung Cancer : Patients with squamous cell carcinoma (prospectively stratified), higher mortality was observed with the addition of Fenitab compared to those treated with carboplatin and paclitaxel alone. Interactions with UGT1A1 Substrates : Fenitab can cause increases in plasma concentrations of drugs that are substrates of UGT1A1. Interaction with Docetaxel & Doxorubicin : Fenitab can cause increases in plasma concentrations of Docetaxel and Doxorubicin. Hepatic Impairment : Hepatic impairment may reduce plasma concentrations of Fenitab. Neomycin : Co-administration of oral Neomycin causes a decrease in Fenitab exposure.